Announcements Trials
Browse Landscape

Phase

Phase NA 12Phase EARLY_PHASE1 1Phase 4 1Phase 3 1Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 8Thoracic 2Lymphoid 1Head & Neck 1Endocrine 1Dermatologic 1Classical hematology 1

Conditions

Squamous Cell Carcinoma of Head and Neck 618Head and Neck Neoplasms 599Nasopharyngeal Carcinoma 230Thyroid Neoplasms 148Oropharyngeal Neoplasms 104Carcinoma, Squamous Cell 90Salivary Gland Neoplasms 88Mouth Neoplasms 87Nasopharyngeal Neoplasms 79Recurrence 66Carcinoma, Non-Small-Cell Lung 66Laryngeal Neoplasms 60Neoplasm Metastasis 58Neoplasms 49Hypopharyngeal Neoplasms 45Thyroid Carcinoma, Anaplastic 42Thyroid Cancer, Papillary 42Melanoma 38Breast Neoplasms 36Lung Neoplasms 34Adenocarcinoma, Follicular 33Carcinoma 32Tongue Neoplasms 30Sarcoma 29Uterine Cervical Neoplasms 28Stomatitis 28Colorectal Neoplasms 28Carcinoma, Medullary 24Ovarian Neoplasms 23Esophageal Neoplasms 23

Interventions

Venlafaxine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Depression × Head & Neck × Clear all
NCT05724849 2024-01-18

Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer

Vanderbilt University Medical Center

Phase 2 Withdrawn
Head & Neck

Depression, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡